SeaStar Medical Holding (Nasdaq:ICU) - Hisse Senedi Fiyatı, Haberler ve Analizler

ICU Stoklara Genel Bakış

ICU temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Gelirin yılda 176.26% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $68K )

Negatif hissedar öz sermayesi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

1 yıldan az nakit akışı var

+ 3 daha fazla risk

SeaStar Medical Holding Corporation Rakipler

Beyond Air

NasdaqCM:XAIR

US$48.1m

PetVivo Holdings

OTCPK:PETV

US$10.5m

Lifeward

NasdaqCM:LFWD

US$18.1m

Sintx Technologies

NasdaqCM:SINT

US$6.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti SeaStar Medical Holding
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.54
52 Haftanın En Yüksek Seviyesi	US$42.92
52 Haftanın En Düşük Seviyesi	US$1.83
Beta	-1.06
11 Aylık Değişim	-28.65%
3 Aylık Değişim	-51.89%
1 Yıllık Değişim	-80.42%
33 Yıllık Değişim	-98.99%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-98.96%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	ICU	US Medical Equipment	US Pazar
7D	18.1%	1.7%	1.6%
1Y	-80.4%	22.5%	32.3%

Getiri vs. Endüstri: ICU geçen yıl % 22.5 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: ICU geçen yıl % 32.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ICU's price volatile compared to industry and market?
ICU volatility
ICU Average Weekly Movement	12.1%
Medical Equipment Industry Average Movement	7.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ICU hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ICU 'nin haftalık oynaklığı son bir yılda 21% dan 12% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	12	Eric Schlorff	www.seastarmedical.com

Bir tıbbi cihaz şirketi olan SeaStar Medical Holding Corporation, Amerika Birleşik Devletleri'nde hiperenflamasyonun hayati organlar üzerindeki sonuçlarını azaltmak için bir platform terapisi geliştirmektedir. Şirket, enfeksiyonları savuşturmak ve vücuttaki hasarlı dokuyu onarmak için enflamatuar yanıt sunmaktadır. Ayrıca CRRT'de pediatrik ve yetişkin akut böbrek hasarı; konjestif kalp yetmezliğinde kardiyorenal sendrom; son evre böbrek hastalığında miyokardiyal stunning; ve hepatorenal sendrom dahil olmak üzere çeşitli terapötik alanlarda ürünler geliştirmektedir.

SeaStar Medical Holding Corporation Temel Bilgiler Özeti

SeaStar Medical Holding'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ICU temel i̇stati̇sti̇kler
Piyasa değeri	US$10.27m
Kazançlar(TTM)	-US$29.87m
Gelir(TTM)	US$68.00k

166.7x

P/S Oranı

-0.4x

F/K Oranı

ICU aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ICU gelir tablosu (TTM)
Gelir	US$68.00k
Gelir Maliyeti	US$0
Brüt Kâr	US$68.00k
Diğer Giderler	US$29.94m
Kazançlar	-US$29.87m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-6.69
Brüt Marj	100.00%
Net Kâr Marjı	-43,923.53%
Borç/Özkaynak Oranı	0%

ICU uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ICU Stoklara Genel Bakış

Ödüller

Risk Analizi

SeaStar Medical Holding Corporation Rakipler

NasdaqCM:XAIR

US$48.1m

OTCPK:PETV

US$10.5m

NasdaqCM:LFWD

US$18.1m

NasdaqCM:SINT

US$6.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

Recent updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

SeaStar Medical Holding Corporation Announces First Pediatric Patient Treated in A Commercial Setting with FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Holding Corporation has completed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

The Schall Law Firm Reminds Class Action Lawsuit Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Corporation Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

High number of new and inexperienced directors

SeaStar Medical Holding Announces Compliance Update with Nasdaq Listing Rule 5550(b)(2) and Nasdaq Listing Rule 5550(a)(2)

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announced delayed annual 10-K filing

Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

FDA Grants Humanitarian Device Exemption Approval to Seastar Medical’S Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department Regarding the Company Regains Compliance with the Market Value Rule

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Holding Receives Non-Compliance Notice from Nasdaq

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

New major risk - Shareholder dilution

U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device

SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Seastar Medical Holding Receives Nasdaq Staff Deficiency Letter Regarding Non-Compliance with Market Value of Listed Securities Requirements

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 28, 2023

SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

High number of new directors

Seastar Medical Appoints Rick Barnett as Chairman of the Board of Directors

No independent directors

SeaStar Medical Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

SeaStar Medical Holding Corporation Temel Bilgiler Özeti

166.7x

-0.4x

Kazanç ve Gelir